2.89
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nanosonics
Its shares trade on ASX under the ticker NAN.AX. It has been listed since 17 May 2007. In the fiscal year to 30 June 2026, it reported revenue of A$203.5m and net income of A$17.8m. At that date it held total assets of A$310.5m and shareholders' equity of A$217.5m.
Nanosonics Ltd. engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-05-17. The Company’s principal activities include manufacturing and distribution of the trophon ultrasound probe disinfector and its associated consumables and accessories and research, development and commercialization of infection control and decontamination products and related technologies. The Company’s automated Trophon electron paramagnetic resonance (EPR) disinfection device provides solutions for care in ultrasound probe disinfection practices. trophon is its solution for reducing cross contamination between patients and reducing the spread of Healthcare Acquired Infections (HAIs). Its trophon2 product includes AcuTrace technology, which enables digital record keeping and provides workflows for ultrasound probe high level disinfection. Its consumable and accessories include NanoNebulant, trophon Chemical Indicator, trophon AcuTrace Operator Card and trophon Printer.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 17 May 2007
- Employees
- 286
- Website
- nanosonics.com.au ↗
Leadership
Pay as last reported
- Mr. Steven SargentIndependent Chairman of the BoardA$247,500
- Mr. Michael KavanaghPresident, Chief Executive Officer, Managing Director, Executive Director, since 2012A$2.1m
- Mr. Jason BurrissChief Financial OfficerA$560,107
- Mr. Ken ShawRegional President for the United States, Canada and Latin AmericaA$659,223
- Mr. Ronan WrightRegional President for Europe, Middle East and Africa
- Mr. Rod LopezChief Operating OfficerA$834,555
- Ms. Jodi SampsonChief People and Culture Officer
- Mr. Sunny PillaiChief Information Officer
- Mr. Matthew LipscombeChief Marketing Officer
- Mr. Jonathan BurdachChief Medical Affairs and Scientific Officer
- Mr. Matthew CarbinesGeneral Counsel, Company Secretary
- Dr. Tracey BattenNon-Executive DirectorA$104,405
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 87
- Environment
- 98
- Social
- 99
- Governance
- 63
- Direct emissions (scope 1)
- 77.1 t
- Energy emissions (scope 2)
- 609.8 t
- Value chain emissions (scope 3)
- 17,117 t
- Women in the workforce
- 44%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nanosonics Ltd has a strong brand reputation in the industry, which helps in building customer trust and loyalty.
- The company offers innovative and technologically advanced products, giving them a competitive edge in the market.
- Their proprietary technology ensures high-quality and efficient disinfection, ensuring customer satisfaction.
Weaknesses
- Nanosonics Ltd operates in a highly competitive market, making it challenging to maintain market share and profitability.
- The company has a limited product portfolio and may be overly dependent on a single product or market segment.
- Their products may have a higher price point compared to competitors, potentially limiting market penetration.
Opportunities
- There is a growing global demand for effective infection prevention and control solutions, presenting opportunities for Nanosonics to expand its market reach.
- The healthcare sector is constantly evolving, creating opportunities for the development of new products and technologies.
- Nanosonics can explore partnerships or collaborations with healthcare organizations to improve market access and distribution channels.
Threats
- Intense competition from existing and new players in the industry poses a threat to Nanosonics' market position.
- Economic downturns or fluctuations could impact healthcare spending, affecting the demand for Nanosonics' products.
- Regulatory changes or compliance requirements may pose challenges for the company in terms of adapting to new standards or obtaining necessary certifications.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.